Point72 Asset Management’s ADMA Biologics ADMA Stock Holding History

Point72 Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.6M	Buy	3,288,757 +2,894,878	+735%	+$45.7M	0.04%	614
2025 Q4	$7.18M	Sell	393,879 -928,137	-70%	-$15.6M	0.01%	1566
2025 Q3	$19.4M	Buy	+1,322,016	New	+$22.7M	0.03%	563
2025 Q2	–	Sell	-847,558	Closed	-$16.8M	–	2132
2025 Q1	$16.8M	Buy	847,558 +635,232	+299%	+$11M	0.04%	498
2024 Q4	$3.64M	Buy	212,326 +101,315	+91%	+$1.91M	0.01%	1045
2024 Q3	$2.22M	Buy	111,011 +7,556	+7%	+$118K	0.01%	1162
2024 Q2	$1.16M	Buy	+103,455	New	+$868K	﹤0.01%	1236
2024 Q1	–	Sell	-244,513	Closed	-$1.11M	–	2122
2023 Q4	$1.11M	Buy	+244,513	New	+$905K	﹤0.01%	1377
2023 Q2	–	Sell	-1,934,576	Closed	-$6.4M	–	2118
2023 Q1	$6.4M	Sell	1,934,576 -56,524	-3%	-$195K	0.02%	690
2022 Q4	$7.73M	Buy	+1,991,100	New	+$6.14M	0.03%	632
2020 Q2	–	Sell	-250,000	Closed	-$720K	–	782
2020 Q1	$720K	Buy	+250,000	New	+$864K	0.01%	635

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Point72 Asset Management's ADMA Position: Q1 2026 in Review

Point72 Asset Management increased its ADMA Biologics (ADMA) stake by 735% in Q1 2026, buying an estimated $45.7M and bringing the position to 3,288,757 shares worth $29.6M. The position accounts for 0.04% of the portfolio, ranked #614.

Point72 Asset Management first reported a position in ADMA in Q1 2020 and has held it in 11 quarters since. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

Point72 Asset Management held 3,288,757 shares of ADMA Biologics worth $29.6M as of Q1 2026.
Point72 Asset Management bought 2,894,878 ADMA Biologics shares in Q1 2026, an estimated $45.7M.
ADMA Biologics made up 0.04% of Point72 Asset Management's portfolio in Q1 2026, its #614 holding.
Point72 Asset Management first reported a position in ADMA Biologics in Q1 2020 and has held it in 11 quarters since.
356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.